When.com Web Search

  1. Ads

    related to: nanobody drug approved supplements

Search results

  1. Results From The WOW.Com Content Network
  2. Single-domain antibody - Wikipedia

    en.wikipedia.org/wiki/Single-domain_antibody

    A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (V H) of a heavy-chain antibody, or of a common IgG.These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea.

  3. Nootropic - Wikipedia

    en.wikipedia.org/wiki/Nootropic

    Nootropics (/ n oʊ. ə ˈ t r oʊ p ɪ k s / noh-ə-TROHP-iks or / n oʊ. ə ˈ t r ɒ p ɪ k s / noh-ə-TROP-iks), [1] colloquially brain supplements, smart drugs and cognitive enhancers, are natural, semisynthetic or synthetic compounds which purportedly improve cognitive functions, such as executive functions, attention or memory.

  4. Muromonab-CD3 - Wikipedia

    en.wikipedia.org/wiki/Muromonab-CD3

    Muromonab-CD3 was approved by the U.S. Food and Drug Administration (FDA) in 1986, [5] making it the first monoclonal antibody to be approved anywhere as a drug for humans. In the European Communities , it is the first drug to be approved under the directive 87/22/EWG, a precursor of the European Medicines Agency (EMA) centralised approval ...

  5. Antibody–drug conjugate - Wikipedia

    en.wikipedia.org/wiki/Antibody–drug_conjugate

    Schematic structure of an antibody–drug conjugate (ADC) Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were ...

  6. Bispecific monoclonal antibody - Wikipedia

    en.wikipedia.org/wiki/Bispecific_monoclonal_antibody

    Additional bispecific antibody drugs have since been approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. [31] Among the bsAb programs currently under development, the combination of CD3 and tumor surface targets are the most popular targets pairs.

  7. Trodusquemine - Wikipedia

    en.wikipedia.org/wiki/Trodusquemine

    Trodusquemine is an aminosterol (polyamine steroid conjugate) that inhibits protein tyrosine phosphatase 1B (PTP1B) activity. [1] The compound exhibits broad-spectrum antimicrobial activity [2] and numerous regenerative, neuroprotective, anti-atherosclerotic, antitumor, antiangiogenic, antiobesity, and anxiolytic properties. [3]

  8. Antibody-oligonucleotide conjugate - Wikipedia

    en.wikipedia.org/wiki/Antibody-oligonucleotide...

    A straightforward uptake, like for most small-molecule drugs, is hindered by the polyanionic backbone and the molecular size of ONs. Being adapted from the broad and successful class of Antibody-Drug conjugates , antibodies and antibody analogues are more and more used in research in order to overcome hurdles related to delivery and ...

  9. Ionis Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Ionis_Pharmaceuticals

    Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...